Research Papers:

Clinicopathologic study of invasive micropapillary carcinoma of the breast

Shen-li Tang, Ji-qiao Yang, Zheng-gui Du, Qiu-wen Tan, Yu-ting Zhou, Di Zhang and Qing Lv _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:42455-42465. https://doi.org/10.18632/oncotarget.16405

Metrics: PDF 1759 views  |   HTML 4421 views  |   ?  


Shen-li Tang1,2, Ji-qiao Yang1,2, Zheng-gui Du1,2, Qiu-wen Tan1,2, Yu-ting Zhou1,2, Di Zhang1,2 and Qing Lv1,2

1Department of Breast Surgery, West China Hospital/West China School of Medicine, Sichuan University, 610041, P.R. China

2Laboratory of Breast Disease, West China Hospital/West China School of Medicine, Sichuan University, 610041, P.R. China

Correspondence to:

Qing Lv, email: [email protected]

Keywords: breast cancer, invasive micropapillary carcinoma, locoregional recurrence, prognostic factors, survival

Received: September 20, 2016    Accepted: February 21, 2017    Published: March 21, 2017


Invasive micropapillary carcinoma (IMPC) is a rare subtype of breast carcinoma. It is presumed to be more aggressive than invasive ductal carcinoma (IDC), though it is uncertain whether the prognoses of IMPC and IDC differ. In this retrospective study, we compared the clinicopathologic characteristics and survival between 170 female patients with IMPC (pure or mixed with IDC) and 728 with pure IDC. The IMPC patients had higher clinical stages and histologic grades, higher incidences of lymphovascular invasion and axillary lymph node extracapsular extension, and a higher degree of lymph node involvement than IDC patients. Moreover, IMPC was associated with increases in estrogen receptor (ER) and progesterone receptor (PR) positivity and HER-2 overexpression. Although locoregional recurrence-free survival (LRRFS) and recurrence-free survival (RFS) were poorer in IMPC patients than IDC patients, overall survival and distant metastasis survival did not differ between the two groups. Multivariate analysis revealed that IMPC was an independent prognostic factor for LRRFS in breast cancer, and IMPC patients had poorer clinicopathologic characteristics and poorer RFS and LRRFS than IDC patients. We therefore suggest that to improve treatment decisions, patients with breast carcinoma be tested for the presence of this specific subtype.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16405